Lupin gains post USFDA approval

Lupin announced on Friday that it has received approval from USFDA for Fosaprepitant for Injection. The shares of Lupin gained over 1 per cent on BSE.

The pharma company received USFDA approval for Fosaprepitant for Injection 150 mg Single-Dose Vial, from the United States Food and Drug Administration (USFDA). Lupin's Fosaprepitant for Injection, is the generic version of Emend for Injection, 150 mg Single-Dose Vial, of Merck Sharp & Dohme Corp. (Merck)

Fosaprepitant is indicated for adults in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

According to IQVIA MAT June 2019, Fosaprepitant for Injection, 150 mg Single-Dose Vial, had annual sales of approximately USD 285 million in the United States.

 Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

The shares of Lupin on Friday had opened at Rs. 767.00 against Thursday’s close of Rs. 765.55. At closing hours, it was trading at Rs. 772.25, gaining 0.88 per cent from its previous close. The stock hit an intraday high of Rs. 774.85 and intraday low was Rs. 757.50. Its 52-week high was Rs. 774.85 and 52-week low was Rs. 711.60 per share on the BSE.